STOCK TITAN

UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock. The filing lists the sale date as 05/08/2026 with aggregate proceeds of $300,048.00. The underlying shares were issued on 01/27/2023 following a stock option exercise.

Positive

  • None.

Negative

  • None.

Insights

Form 144 sale notice for 10,000 shares with $300,048 proceeds.

The filing lists a 10,000-share sale reported on 05/08/2026, showing aggregate proceeds of $300,048.00. The shares trace to a stock option exercise dated 01/27/2023.

Regulatory treatment appears routine: the notice documents a broker-assisted resale on NASDAQ through RBC Capital Markets. Timing, selling holder identity, and whether sales were part of a larger plan are not detailed in the excerpt.

Shares sold 10,000 shares sale date <date>05/08/2026</date>
Aggregate proceeds $300,048.00 proceeds reported in Form 144
Origin of shares Stock option exercise exercise date <date>01/27/2023</date>
Form 144 regulatory
"Form 144 notice showing the sale of 10,000 shares"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Stock option exercise financial
"STOCK OPTION EXERCISE | ISSUER | 01/27/2023"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Aggregate proceeds financial
"10000 | 300048.00"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does UroGen's (URGN) Form 144 report show?

The Form 144 reports a sale of 10,000 shares of common stock for $300,048.00, with the sale date listed as 05/08/2026. The shares originated from a stock option exercise dated 01/27/2023.

Who acted as broker for the sale reported in the Form 144?

RBC Capital Markets LLC is named as the broker-dealer in the filing, with an address in Minneapolis. The filing indicates the transaction was executed on NASDAQ and routed through that brokerage firm.

Does the Form 144 specify who the selling holder is?

The filing identifies a contact name, Mark Schoenberg, associated with RBC Capital Markets. The excerpt does not provide a broader selling-stockholder table or additional beneficial-ownership details for the holder.

Are the proceeds and origin of the shares disclosed?

Yes. The excerpt shows aggregate proceeds of $300,048.00 for 10,000 shares, and indicates the shares were issued following a stock option exercise on 01/27/2023.